Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2023 Results Conference Call May 3, 2023 8:30 AM ET Company Participants Susan Mesco - Head of IR David Stack - CEO Ron Ellis - Chief Strategy Officer Charles Reinhart - CFO Conference Call Participants David Amsellem - Piper Sandler Glen Santangelo - Jefferies Gregory Renza - RBC Capital Markets Greg Fraser - Truist Securities Rohit Bhasin - Needham & Co Operator Good day, and thank you for standing by. Welcome to the Q1 2023 Pacira BioSciences Inc Earnings Confere ...

Sales Performance - Total net product sales increased by 23% in 2022, reaching $664.2 million compared to $539.0 million in 2021[429]. - EXPAREL net product sales grew by 6% to $536.9 million in 2022, driven by a 5.5% increase in gross vial volume and a 3.6% rise in gross selling price per unit[430]. - ZILRETTA net product sales surged by 100% to $105.5 million in 2022, following its acquisition in November 2021[431]. - iovera° sales decreased by 6% to $15.3 million in 2022, attributed to a delay in product transition and reimbursement policy variations[432]. - Bupivacaine liposome injectable suspension revenue increased by 80% in 2022, primarily due to the sales mix for veterinary use[433]. Cost and Expenses - Cost of goods sold rose by 42% to $199.3 million in 2022, impacting the gross margin which decreased from 74% in 2021 to 70% in 2022[436]. - Total research and development expenses increased by 53% in 2022, reaching $84.8 million compared to $55.5 million in 2021, representing 13% of total revenue[438]. - Clinical and preclinical development expenses surged by 89% in 2022 to $45.6 million, driven by ongoing trials and the completion of two EXPAREL trials[439]. - Product development and manufacturing capacity expansion expenses rose by 27% in 2022 to $24.6 million, primarily due to scaling up EXPAREL manufacturing capacity[440]. - Selling, general and administrative expenses increased by 28% in 2022, totaling $254.5 million, which is 38% of total revenue[445]. - Sales and marketing expenses grew by 31% in 2022 to $145.0 million, influenced by the expansion of the sales force and marketing investments for ZILRETTA and iovera°[446]. - Amortization of acquired intangible assets skyrocketed by 100% in 2022 to $57.3 million, reflecting the first full year post-Flexion Acquisition[450]. Financial Position - As of December 31, 2022, the company had cash and cash equivalents of $325.9 million and working capital of $350.6 million, indicating strong liquidity[460]. - The company recorded an income tax benefit of $2.6 million in 2022, contrasting with an income tax expense of $14.4 million in 2021[459]. - Interest expense increased by 26% in 2022 to $40.0 million, attributed to a $375.0 million Term Loan taken in December 2021[456]. - The company recognized acquisition-related gains of $18.2 million in 2022, primarily due to adjustments in contingent consideration liabilities[451]. Cash Flow - In 2022, net cash provided by operating activities was $145.3 million, an increase of 15.6% from $125.7 million in 2021[464]. - Net cash used in investing activities in 2022 was $225.2 million, significantly higher than $20.8 million in 2021, primarily due to $150.1 million in available-for-sale investment purchases and a $32.0 million milestone payment related to the Pacira acquisition[465][466]. - Net cash used by financing activities in 2022 was $401.5 million, compared to a net cash inflow of $380.7 million in 2021, driven by principal repayments on the Flexion 2024 Notes and 2022 Notes[467][468]. Future Outlook and Plans - The company expects to continue expanding the use of EXPAREL, ZILRETTA, and iovera° in additional procedures and invest in manufacturing capacity[420]. - The company plans to continue expanding the commercialization of its products, including EXPAREL and ZILRETTA, both domestically and internationally[484]. - The company may require additional debt or equity financing to meet future operating and capital requirements, with no committed external sources of funds currently available[479]. Acquisition and Obligations - The Flexion Acquisition in November 2021 involved total consideration of $578.8 million, including an initial cash payment of $428.3 million[423]. - The company anticipates potential milestone payments of up to $372.3 million related to the Flexion acquisition, contingent on achieving certain regulatory and commercial milestones[477][483]. - The company has contractual obligations of $8.6 million due on the 2024 Notes in May 2024 and $402.5 million due on the 2025 Notes in August 2025[480]. - As of December 31, 2022, the maximum remaining potential payments related to contingent consideration from the Flexion Acquisition is $372.3 million[490]. Risk Factors - Accounts receivable are primarily concentrated with four large wholesalers, posing a risk of material adverse impact on financial condition if non-performance occurs[496].

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive Officer Roy Winston - Chief Medical Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Glen Santangelo - Jefferies Gregory Renza - RBC Capital Markets Oren Livnat - H.C. Wainwright Andreas Argyrides - Wedbush Greg Fraser - Truist Securities Operator Go ...

• Ex-U.S. market expansion in 2023 • Significant upside in current and new markets 7 EXPAREL Penetration Market Procedures Orthopedics General Surgery Women's Health Cardiothoracic OMFS 18M 1M 3M 6M ~34M 6M Potential Procedures1 slowdown in growth in 2022 %YoY Growth (Moving Annual Total) 2020 vs 2021 2021 vs 2022 2021 2022 -25 -20 -15 -10 -5 0 5 10 15 20 25 30 35 1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 55 58 61 64 67 70 73 76 79 82 85 88 91 94 W44 W26 YE W26 W44 MAT YoY recovery from 2020 lockdo ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive Officer Roy Winston - Chief Medical Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Serge Belanger - Needham Gary Nachman - BMO Capital Markets Susan Mesco Good morning everyone. Welcome to today's conference call to discuss our Third Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) 5401 West Kennedy Boulevard, Suite 890 Tam ...

Pacira Biosciences Inc. (NASDAQ:PCRX) Q2 2022 Results Conference Call August 3, 2022 8:30 AM ET Company Participants Susan Mesco - Head, IR Dave Stack - Chairman, CEO Charlie Reinhart - CFO Conference Call Participants David Amsellem - Piper Sandler Chris Neyor - JP Morgan Balaji Prasad - Barclays Gregory Renza - RBC Capital Markets Greg Fraser - Truist Securities Serge Belanger - Needham Operator Ladies and gentlemen, thank you for standing by, and welcome to the Pacira BioScience's Second Quarter 2022 Ear ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Susan Mesco – Head-Investor Relations Dave Stack – Chairman and Chief Executive Officer Charlie Reinhart – Chief Financial Officer Conference Call Participants David Amsellem – Piper Sandler Gregory Renza – RBC Capital Markets Greg Fraser – Truist Securities Anita Dushyanth – Berenberg Capital Serge Belanger – Needham & Company Evan Hua – BMO Capital Operator Thank you for standing by, and wel ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorpora ...

Table of Contents, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (State ...